Fuqua Professor David Ridley

Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.

Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...

Adding Immix Biopharma (IMMX) to 2022 Biotech 12 Pack List.

Added to 12 Biotech Stocks we Expect to Double List. The Original Biotech 6-Pack from 2020, is Growing to...
Roland Rick Perry

Tax Loss Selling Bargain? Adding Aditxt (ADTX).

Adding Aditxt (ADTX) to the upcoming "2022 Biotech 6-Pack, Stocks We Expect to Double" Watch List.

Dalrada (DFCO). Our 11th and Latest Ten Bagger.

We've actually had many more than 11 ten-baggers, as we report on companies which aren't clients. This is our 11th client we...

The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...

The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21. Revive Therapeutics (RVTTF), RedHill BioPharma...

News and Charts on Four Small Cap Telehealth and Remote Health Monitoring Plays.

After Losing $33 Billion in Value, Teladoc Health Snags an Upgrade. With chances building...

He Shoots and He Scores. Dicerna (DRNA) up 78%.

Our Second $3.00 Watch List Company Gets Acquired for Over $1 Billion. As They say "You Can't Make This **** Up."

Avicanna (AVCNF) $0.60 Conference Call.

8:30EST This Morning, Friday 11/12/21 Avicanna Inc. to Host Third Quarter 2021 Investor Conference Call. TORONTO,...

And We Have Our First MEME Stock! $2.00 to $29.95.

Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg) Guess we were bound to stumble across...

ABVC BioPharma (ABVC) Approved for ABV-1505 Phase II Part II in Taiwan Sites

Gentleman, Start Your Engines? ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study

Latest article

Revive therapeutics

Our Best Risk to Reward Idea Ever?

Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 pack, 12 Biotech Stocks We Expect to...
Immunix Bio

ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.

Demonstrates 100% Completion of Planned Treatment Cycles. Immix Biopharma, Inc. Wed, January 19, 2022. ImmixBio...
Fuqua Professor David Ridley

Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.

Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...